Does the 100-μg dose of the SARS-CoV-2 mRNA-1273 vaccine improve immunogenicity compared to the 25-μg dose in older adults?
The 100-μg dose of the mRNA-1273 vaccine is safe and more immunogenic than the 25-μg dose in older adults, supporting its use in phase 3 trials.
In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461.).
Anderson et al. (Tue,) studied this question.